Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Ceftiofur is a third-generation cephalosporin antibiotic developed for veterinary medicine. It is a semisynthetic, beta-lactamase-stable, broad-spectrum antimicrobial agent effective against both Gram-positive and Gram-negative bacteria. Its mechanism of action involves inhibiting bacterial cell wall synthesis by binding to and inactivating penicillin-binding proteins (PBPs), which are essential for bacterial cell wall formation, ultimately leading to bacterial cell lysis. Ceftiofur is widely used to treat various bacterial infections in livestock and companion animals, including respiratory diseases, foot rot, metritis, and mastitis. It is marketed by companies such as Zoetis.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on ceftiofur.